ANTEOTECH LTD — Capital/Financing Update 2015

Jul 7, 2015

==> picture [315 x 91] intentionally omitted <==

ANTEO ANNOUNCES A PRODUCT DEVELOPMENT AGREEMENT WITH IMRA

Highlights

• Anteo and IMRA America complete feasibility study, evaluating the combined use of Mix&Go™ Activation Reagent with IMRA’s proprietary gold colloids

• Proof of concept product developed with excellent results

• Partnership agreement progresses to focus on development of combination products

Brisbane, Australia, 8 July 2015 - Anteo Diagnostics Ltd (ASX: ADO) is pleased to update investors on the progress of its relationship with IMRA America, Inc., (“IMRA”), a world leader in the research, development, manufacturing and application of ultrafast fibre lasers.

On 22 December 2014, Anteo announced that it would collaborate with IMRA to develop a Mix&Go activated Gold Particle Coupling Kit, specifically tailored to IMRA's i-colloid gold product range.

Feasibility study outcomes

Following the 22 December announcement, Anteo and IMRA have been working together on a feasibility study, which considered how best to combine Mix&Go with IMRA’s gold colloids in the development of novel products to be sold within the in vitro diagnostics industry.

The feasibility study has finished and proof of concept has been demonstrated with excellent results. Key outcomes from the study include:

• The successful combination of Anteo’s Mix&Go Activation Reagent with IMRA’s proprietary gold colloids

• The combination yielded high purity, high quality pre-activated gold particles that are ready-to-use

• Clear demonstration that the planned product concept will deliver a number of novel functions not available to the market today, including, ease-of-use (single buffer, fast protein coupling) and shortened assay product development cycles for manufacturers

As a consequence of the study, the two parties have agreed to take the collaboration to the next stage and enter into a funded Product Development Agreement. The resultant products are expected to deliver improvements to the colloidal stability and functionality of gold particles, leading to cheaper, improved assays and more accurate results.

An important long-term partnership

Anteo and IMRA America will work closely together during the coming 6 months with the clear objective of delivering products ready for sale. The initial focus will be on validating the proof of concept product built during the feasibility study.

==> picture [115 x 87] intentionally omitted <==

==> picture [268 x 55] intentionally omitted <==

==> picture [315 x 91] intentionally omitted <==

Rachel de las Heras, Head of Commercialisation of Anteo commented, “Our Mix&Go technology together with IMRA’s high quality gold particles and comprehensive understanding of metal chelation, have allowed a strong mutual relationship that is reflected in this next stage of our partnership.

With the positive feasibility study results at hand, we are confident that together, we can develop novel and widely applicable products that will see the IMRA and Anteo partnership deliver a range of valuable solutions to the market.”

Speaking on behalf of IMRA America, Dr. Makoto Yoshida, Executive Vice President, Research and Development said, “We have had a fruitful first stage of collaboration with encouraging outcomes. We expect to push this relationship further and develop outstanding products contributing to the biomedical and other societies.”

-END-

About IMRA America

IMRA America, Inc. is dedicated to creative research and innovation leading to the development of essential technologies for industrial use. Their history as the oldest and most experienced femtosecond fibre laser company reflects the successful implementation of breakthrough technologies. IMRA takes the novel approach of ultrafast pulsed laser ablation directly in liquid solvents where the ablated material forms a stable colloidal suspension without using stabilising agents. Their proprietary production method increases the gold nanoparticle surface area available for binding biomolecules.

About Anteo

Anteo Technologies Pty. Ltd, a wholly owned subsidiary of Anteo Diagnostics Ltd (ASX: ADO), is transforming the way scientists work by providing new, powerful tools developed with their patented Mix&Go™ Activation Reagent that significantly advances traditional assay development methods. In turn, helping to reduce assay development costs, improve medical devices and in-vitro diagnostics, leading to the earlier detection of disease. http://anteotech.com

==> picture [596 x 138] intentionally omitted <==